138 related articles for article (PubMed ID: 21225494)
1. Comparison of two different immunohistochemical algorithms identifying prognostic subgroups of DLBCL.
Jabłońska J; Jesionek-Kupnicka D; Potemski P; Kowalik A; Sygut J; Kordek R
Pol J Pathol; 2010; 61(3):124-32. PubMed ID: 21225494
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
Laszlo D; Pruneri G; Andreola G; Radice D; Calabrese L; Rafaniello PR; Nassi L; Sammassimo S; Alietti A; Agazzi A; Vanazzi A; Martinelli G
Int J Surg Pathol; 2011 Aug; 19(4):417-24. PubMed ID: 19793830
[TBL] [Abstract][Full Text] [Related]
3. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma].
Li M; Liu CL; Wang XY; Xue XM; Gao ZF
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229
[TBL] [Abstract][Full Text] [Related]
5. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified.
Hwang HS; Park CS; Yoon DH; Suh C; Huh J
Am J Surg Pathol; 2014 Aug; 38(8):1046-57. PubMed ID: 24705314
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
Zinzani PL; Broccoli A; Stefoni V; Musuraca G; Abruzzese E; De Renzo A; Cantonetti M; Bacci F; Baccarani M; Pileri SA
Cancer; 2010 Dec; 116(24):5667-75. PubMed ID: 20737566
[TBL] [Abstract][Full Text] [Related]
7. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
9. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab.
Benesova K; Forsterova K; Votavova H; Campr V; Stritesky J; Velenska Z; Prochazka B; Pytlik R; Trneny M
Neoplasma; 2013; 60(1):68-73. PubMed ID: 23067219
[TBL] [Abstract][Full Text] [Related]
10. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
11. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
12. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
[TBL] [Abstract][Full Text] [Related]
13. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
14. Tissue microarray in a subset of South African patients with DLBCL.
Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
Song MK; Chung JS; Sung-Yong O; Lee GW; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ; Shin DH; Yun EY
Ann Hematol; 2010 Oct; 89(10):985-91. PubMed ID: 20428871
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.
Saad AA; Awed NM; Abdel-Hafeez ZM; Kamal GM; Elsallaly HM; Alloub AI
Saudi Med J; 2010 Feb; 31(2):135-41. PubMed ID: 20174727
[TBL] [Abstract][Full Text] [Related]
18. [Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma].
Zeng LP; Wen YL; Ma Y; Wang GQ; Li Y; Wang J; Xu LL; Zhang XM
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):377-81. PubMed ID: 21914345
[TBL] [Abstract][Full Text] [Related]
19. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN
Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
